A fermentation of a milk source with Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) to form a fermented milk product. The fermented milk product has at least a cream flavour and aroma. The fermented milk product can be in the form of a powder or a concentrate. The fermented milk product has applications in the food industry. A use of a lactic acid bacterium, Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4404) or a Lactococcus lactis subsp. lactis diacetylactis (CNCM No. I-4405) for the manufacture of butter-cream flavouring milk ingredients containing at least one of diacetyl, acetoin and 3,4-dihydroxy-3,4-dimethyl-2,5-hexanedione.

Isolates strains of gastrointestinal bacteria from wolves are provided for use as probiotics. In some embodiments, the isolated strains are for use as probiotics in canine subjects such as domestic dogs. In some embodiments, the isolated strains may be used to treat or prevent intestinal dysbiosis in the subject. Also provided are compositions comprising at least one isolated strain of wolf probiotic bacteria and related methods for making same.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1.fwdarw.3) glucose 2 (1.fwdarw.3) rhamnose (1.fwdarw.3) ribitol (5.fwdarw.phosphate}. This new serotype may be included in pneumococcal vaccines.

The present invention relates to a method for obtaining a lactic acid bacteria strain which results in a high mechanical shear resistance of the products fermented with the strain and to bacteria strains obtainable by such a method. Furthermore, the present invention relates to lactic acid bacteria strains which results in a high resistance towards mechanical shear treatment of the products fermented with the strains or mutants and variants thereof. The improved stability of the texture can be measured as reduced sedimentation in drinking yoghurt applications and reduced syneresis in set-type yoghurt applications. Thus, the present invention also relates to methods for preparation of a fermented milk product, such as a yoghurt, with such lactic acid bacteria strains and to such fermented milk products.

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

This invention provides lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect and that can be used with high safety. This invention further provides a pharmaceutical preparation comprising, as an active ingredient, lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect. According to the invention, novel lactic acid bacteria belonging to the Enterococcus faecium species having particular mycological properties and exhibiting viability of 40% or higher when freeze-dried in the absence of a dispersion medium and viability of 80% or higher in a probiotic preparation when stored at 40° C. for 4 months, a composition comprising such lactic acid bacteria, an agent for ameliorating fatigue, improving blood circulation, reducing stool odor or promoting growth comprising, as an active ingredient, such composition, and use of such composition for food and other products.

Provided is a novel lactic acid bacterium strain which is capable of suppressing production of volatile sulfur compounds by oral bacteria, has no cariogenicity and no causative role in infective endocarditis, and is safe in an oral cavity, and provided is an agent for preventing, improving and/or treating oral diseases and discomforts by use of the bacterial strain. An agent for preventing and/or treating an oral disease, containing, as an active ingredient, at least one lactic acid bacterium selected from Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, and Streptococcus mitis and having all of the following properties (1) to (6): (1) having no ability to produce a volatile sulfur compound (VSC); (2) having no ability to produce water-insoluble glucan; (3) having adhesiveness to a tooth surface and/or an oral cell; (4) having a growth inhibitory effect on a bad breath-causing bacterium and/or a periodontal pathogen; (5) having no causative role in infective endocarditis; and (6) having no cariogenicity.

Bacteriophage Insensitive Mutants (BIMs) of three Streptococcus thermophilus parent strains were generated and characterized for phage sensitivity, sedimentation rate, cell chain length, phage adsorption and CRISPR loci alterations. Several BIMs showed an altered sedimentation phenotype as well as an increase cell chain length, reduced phage sensitivity, reduced phage adsorption and 100% identity in three CRISPR loci. The results show that the derived BIMs have become phage-resistant through a mechanism other than CRISPR.

A medicine, a food or a drink and feed which are effective for preventing and/or improving decline, occurring with age (senescence), in memory and learning ability are provided. A novel microorganism having the effect of preventing and/or improving decline, occurring with age (senescence,) in memory and learning ability is provided. More specifically, the microorganism is characterized by being a microorganism belonging to Lactobacillus, Bifidobacterium, Streptococcus, Leuconostoc or Pediococcus, more specifically a microorganism belonging to any of Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus gallinarum, Lactobacillus johnsonii, Lactobacillus delbrueckii subsp. delbrueckii, Bifidobacterium catenulatum, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophiles, Leuconostoc mesenteroides subsp. dextranicum, Leuconostoc lactis, Pediococcus acidilactici and Pediococcus pentosaceus.

A food composition for alleviating hangovers, the food composition contains, as an active ingredient, at least one strain selected from the group consisting of Lactococcus chungangensis, Lactococcus fujiensis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis, and Lactococcus raffinolactis, or a culture liquid thereof culture medium, wherein functional cream cheese is prepared using five species of Lactococcus strains above having the ability to decompose ethanol and acetaldehyde.